About KromaTiD
KromaTiD is a company based in Fort Collins (United States) founded in 2007. KromaTiD has raised $14.54 million across 13 funding rounds from investors including HHS, Broadoak Capital Partners and NHGRI. KromaTiD offers products and services including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint. KromaTiD operates in a competitive market with competitors including Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others.
- Headquarter Fort Collins, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$14.54 M (USD)
in 13 rounds
-
Latest Funding Round
$7.13 M (USD), Series A
Jul 01, 2025
-
Investors
HHS
& 3 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of KromaTiD
KromaTiD offers a comprehensive portfolio of products and services, including KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint.
Offers single-cell insights for chromosomal integrity in therapy research
Detects chromosome mutations and structural variants
Provides G-Banding for variant analysis
Visualizes structural variants and transgene inserts
Delivers custom probes for detailed genomic testing
People of KromaTiD
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of KromaTiD
KromaTiD has successfully raised a total of $14.54M across 13 strategic funding rounds. The most recent funding activity was a Series A round of $7.13 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in KromaTiD
KromaTiD has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Broadoak Capital Partners and NHGRI.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investment banking services are offered in the United States.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked |
Investor details for KromaTiD
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by KromaTiD
Investment portfolio details for KromaTiD
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - KromaTiD
Detailed financials for KromaTiD
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kromatid Comparisons
Peer comparison for KromaTiD
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of KromaTiD
KromaTiD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Inflammatix, Agendia, PathogenDX, Affymetrix and InDevR, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of diagnostic solutions for systemic infections
|
|
| Locked | Locked | Locked |
Genomic diagnostic products for cancer treatment are provided.
|
|
| Locked | Locked | Locked |
Provider of DNA-based pathogen testing kits
|
|
| Locked | Locked | Locked |
Provider of technologies for multiplex and simultaneous analysis of biological systems at the cell, protein, and gene level
|
|
| Locked | Locked | Locked |
Biotherapeutics, vaccines, and diagnostic products are manufactured and developed.
|
Detailed competitors of KromaTiD
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kromatid
Complete news archive for KromaTiD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about KromaTiD
KromaTiD was founded in 2007 and raised its 1st funding round 6 years after it was founded.
KromaTiD is headquartered in Fort Collins, United States. It is registered at Fort Collins, Colorado, United States.
KromaTiD is a funded company, having raised a total of $14.54M across 13 funding rounds to date.
Provider of molecular and genetic tests for detection of disease-causing mutations, including inversions and translocations, in a single test. Based on its patented Directional Genomic Hybridization (dGH), KromaTiDs assays generate the sequence, location, and orientation data from single cells, making them ideal for mixed cell population studies. KromaTiDs research products and services help in a deeper understanding of genetic diseases, including cancers and developmental disorders.
KromaTiD's top competitors include Inflammatix, PathogenDX and Agendia.
KromaTiD offers KROMASURE™ Platform, KROMASURE™ Screen, KROMASURE™ KBand, KROMASURE™ InSite, and KROMASURE™ PinPoint.
KromaTiD has 4 investors. Key investors include HHS, Broadoak Capital Partners, NHGRI, and First Capital Ventures.